CTI BioPharma Corp. (CTIC)

0.89
NASDAQ : Health Technology
Prev Close 0.86
Day Low/High 0.85 / 0.89
52 Wk Low/High 0.60 / 2.30
Avg Volume 248.60K
Exchange NASDAQ
Shares Outstanding 57.98M
Market Cap 49.84M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Rodman Rambles: The Biotech Dreck

Rodman & Renshaw investor confab brings together some of the biotech sector's worst companies. I listened to them so you don't have to.

Cell Therapeutics Begs for Survival

Cell Therapeutics Begs for Survival

With cash and shares running out, Cell Therapeutics CEO pleads with aggrieved shareholders to extend another lifeline.

Biotech Stock Mailbag: Jazz Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

FDA Advisory Panels: A Coin Flip

FDA advisory panels in 2010 are voting against new drugs more than any other time since 2007.

Biotech Calendar: Key Dates for September

Here's a list of September's potentially stock-moving biotech events

Beacon Power, Orthovita: Volume Movers

Several stocks trading below $5, including Beacon Power, were poised to move on above-average volume Monday.

Biotech Stock Mailbag: Exact Sciences

Biotech Stock Mailbag: Exact Sciences

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Hey, Cell Therapeutics: Where's the Cash?

Cell Therapeutics talked about many positive things on its conference call Thursday. Here's what the company failed to mention.

MELA's Stock Sale Suggests Problems for Skin Cancer Detector

MELA's Stock Sale Suggests Problems for Skin Cancer Detector

MELA's decision to raise money ahead of an August FDA advisory panel suggests raises questions about its MelaFind device.

Biotech Stock Mailbag Readers' Portfolio: Update

The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 11% this year.

Biotech Stock Mailbag: ASCO

Adam Feuerstein answers readers' questions about health care- and drug-related companies.

ASCO Live Blog: Monday

Today is the last day of the American Society of Clinical Oncology annual meeting. Here are the highlights, live.

ASCO Live Blog: Sunday

Here are the highlights from the second full day of clinical data presentations at ASCO 2010.

Biotech Calendar: Key Dates for June

Here's a list of June's potentially stock-moving biotech events.

Sirius, E*Trade See Big Short Increases

Short sellers stepped up their pessimism on Sirius and E*Trade.

Biotech Stock Mailbag: Amarin Pharma

Biotech Stock Mailbag: Amarin Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about healthcare and drug-related stocks.

Cell Therapeutics Seeks Answer to Debt Woes

A proposed stock-for-debt offer still leaves Cell Therapeutics needing cash to survive into next year.

Biotech Stock Mailbag: AspenBio

Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.

Cell Therapeutics, Inc. Q1 2010 Earnings Call Transcript

Cell Therapeutics, Inc. Q1 2010 Earnings Call Transcript

Biotech Stock Mailbag: Labopharm

Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.

Acura Pharma FDA Panel Preview: Updated

An FDA advisory panel will review Acura's abuse-resistant painkiller Acurox on Thursday.

Cell Therapeutics CEO Should Resign: Opinion

If the fight against cancer is a war, Jim Bianco, the CEO of Cell Therapeutics, has been on the losing side of the battlefield his entire career.

Cell Therapeutics Closer to the Brink

FDA rejects Cell Therapeutics' lymphoma drug, pushing the company deeper into financial trouble.

Biotech Calendar: Key Dates for April

Here's a list of April's potentially stock-moving biotech events.

Biotech Stock Mailbag: Myriad Genetics

Our biotech columnist updates the Mailbag Readers' Portfolio and answers questions about Myriad Genetics and other stocks.

ArQule, Cell Therapeutics: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.

Biotech Stock Mailbag: Generex, Part II

Biotech columnist Feuerstein answers readers' questions about Generex, Cell Therapeutics and other stocks.

The End Is Near for Cell Therapeutics

Monday's FDA setback for its cancer drug has ignited a fiscal crisis at Cell Therapeutics which could lead to the company's demise.

Cell Therapeutics' FDA Panel: Live Blog

Read columnist Adam Feuerstein's live blog of the Cell Therapeutics' FDA Panel held on Monday.

Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Action Lawsuit And Seeks To Recover Losses

Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons or ...

TheStreet Quant Rating: D (Sell)